文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症患者急性肾损伤需肾脏替代治疗后严重长期慢性肾病的预测因素:ELVIS随机对照试验的辅助研究

Predictive factors for severe long-term chronic kidney disease after acute kidney injury requiring renal replacement therapy in critically ill patients: an ancillary study of the ELVIS randomized controlled trial.
PubMed 文献 · Crit Care · 2022-11-29
一句话结论ICU急性肾损伤需肾脏替代治疗幸存者中约21%发生严重长期慢性肾病,较长的肾脏替代治疗疗程与12个月内严重慢性肾病相关(OR 1.03/天)。

本研究为多中心ELVIS试验的辅助研究,纳入急性肾损伤需肾脏替代治疗且3个月时存活的患者。按CKD-EPI公式估算肾小球滤过率分期,将患者分为无/轻度慢性肾病组(1-3期)与严重慢性肾病组(4-5期),在3、6、12个月及3、5年时点比较。3个月时183例可随访,其中严重慢性肾病47例(25.7%);5年时122例,严重慢性肾病26例(21.3%)。多因素分析显示较长肾脏替代治疗疗程与12个月内严重慢性肾病相关(ORM12=1.03,95%CI 1.02-1.05,每增加1天),而启动肾脏替代治疗时较高的SOFA评分与5年内严重慢性肾病无关(ORM60=0.85,95%CI 0.77-0.93,每增加1分)。作者认为肾脏替代治疗疗程是严重长期慢性肾病的新预测因素,应在未来预后研究中加以考虑。

要点

  • 急性肾损伤需肾脏替代治疗的ICU幸存者中,3个月时严重慢性肾病(4-5期)占25.7%(47/183),5年时占21.3%(26/122)。
  • 较长肾脏替代治疗疗程与12个月内严重慢性肾病相关:ORM12=1.03(95%CI 1.02-1.05),每增加1天。
  • 启动肾脏替代治疗时较高SOFA评分与5年内严重慢性肾病无关:ORM60=0.85(95%CI 0.77-0.93),每增加1分。
  • 严重长期慢性肾病的发生比例在3个月时为25.7%、5年时为21.3%,提示部分患者肾功能可随时间恢复。
  • 作者认为肾脏替代治疗疗程是严重长期慢性肾病的新预测因素,应在未来预后研究中加以考虑。

适用人群与场景

  • 多中心ELVIS试验人群中的急性肾损伤需肾脏替代治疗患者。
  • 纳入标准:肾脏替代治疗启动后3个月时存活的患者。

诊断标准与关键阈值

  • 慢性肾病分期依据CKD-EPI公式估算的肾小球滤过率确定。
  • 无/轻度慢性肾病组:国际分类1、2、3期(肾功能正常或轻至中度下降)。
  • 严重慢性肾病组:国际分类4、5期。

处置流程与药物剂量

  • 在3、6、12个月及3、5年时点记录血清肌酐水平。

研究设计与关键结果

  • 研究类型:多中心ELVIS随机对照试验的辅助研究;287例符合条件,3个月时183例有随访,其中无/轻度慢性肾病组136例(74.3%)、严重慢性肾病组47例(25.7%)。
  • 5年时122例有随访,其中无/轻度慢性肾病组96例(78.7%)、严重慢性肾病组26例(21.3%)。
  • 多因素分析:较长肾脏替代治疗疗程与12个月内严重慢性肾病相关(ORM12=1.03,95%CI 1.02-1.05,每增加1天)。
  • 多因素分析:启动肾脏替代治疗时较高SOFA评分与5年内严重慢性肾病无关(ORM60=0.85,95%CI 0.77-0.93,每增加1分)。

证据类型、等级与局限

  • 证据类型:多中心随机对照试验的辅助研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为肾脏替代治疗疗程是急性肾损伤患者严重长期慢性肾病的新预测因素,应在未来预后研究中加以考虑。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Acute kidney injury (AKI) requiring renal replacement therapy (RRT) is a serious complication in the ICU that results in increased mortality and risk of chronic kidney disease (CKD). Some studies suggest RRT modality may have an impact on long-term renal recovery after AKI. However, other predictive factors of severe long-term CKD in ICU patients with AKI requiring RRT are unknown.

METHODS: We performed an ancillary study of the multicenter ELVIS trial in the population with AKI requiring RRT. Patients alive 3 months after RRT initiation were eligible. Serum creatinine levels available at 3, 6 and 12 months and 3 and 5 years were recorded. CKD stage was determined according to the glomerular filtration rate as estimated by the CKD-EPI formula. At each timepoint, two groups of patients were compared, a no/mild CKD group with normal or mildly to moderately decreased renal function (stages 1, 2 and 3 of the international classification) and a severe CKD group (stages 4 and 5). Our objective was to identify predictive factors of severe long-term CKD.

RESULTS: Of the 287 eligible patients, 183 had follow-up at 3 months, 136 (74.3%) from the no/mild CKD group and 47 (25.7%) from the severe CKD group, and 122 patients at 5 years comprising 96 (78.7%) from the no/mild CKD group and 26 (21.3%) from the severe CKD group. Multivariate analysis showed that a long RRT period was associated with severe CKD up to 12 months (ORM12 = 1.03 95% CI [1.02-1.05] per day) and that a high SOFA score at the initiation of RRT was not associated with severe CKD up to 5 years (ORM60 = 0.85 95% CI [0.77-0.93] per point).

CONCLUSION: Severe long-term CKD was found in 21% of ICU survivors who underwent RRT for AKI. The duration of the RRT in AKI patients was identified as a new predictive factor for severe long-term CKD. This finding should be taken into consideration in future studies on the prognosis of ICU patients with AKI requiring RRT. Trial registration ELVIS trial was registered with ClinicalTrials.gov, number: NCT00875069 (June 16, 2014), and this ancillary study was registered with ClinicalTrials.gov, number: NCT03302624 (October 6, 2017).

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Soum E, Timsit JF, Ruckly S, et al. Predictive factors for severe long-term chronic kidney disease after acute kidney injury requiring renal replacement therapy in critically ill patients: an ancillary study of the ELVIS randomized controlled trial. Crit Care. 2022. PMID: 36447221. doi:10.1186/s13054-022-04233-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。